16,187 Shares in AxoGen, Inc. (NASDAQ:AXGN) Purchased by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in shares of AxoGen, Inc. (NASDAQ:AXGN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 16,187 shares of the medical equipment provider’s stock, valued at approximately $227,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its position in shares of AxoGen by 8.6% in the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after acquiring an additional 1,651 shares in the last quarter. Roubaix Capital LLC acquired a new stake in AxoGen during the 1st quarter valued at $351,000. Lazard Asset Management LLC lifted its holdings in shares of AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of AxoGen by 8.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,650 shares of the medical equipment provider’s stock worth $240,000 after buying an additional 2,204 shares during the period. Finally, First Light Asset Management LLC grew its holdings in shares of AxoGen by 177.0% during the first quarter. First Light Asset Management LLC now owns 765,886 shares of the medical equipment provider’s stock valued at $6,181,000 after buying an additional 489,397 shares in the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Trading Down 0.1 %

NASDAQ:AXGN opened at $13.15 on Tuesday. The company has a market capitalization of $574.72 million, a P/E ratio of -26.30 and a beta of 1.13. The stock’s 50 day moving average price is $13.35 and its 200 day moving average price is $9.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.32 and a current ratio of 3.51. AxoGen, Inc. has a 52 week low of $3.45 and a 52 week high of $15.23.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. The company had revenue of $47.91 million during the quarter, compared to the consensus estimate of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. On average, research analysts forecast that AxoGen, Inc. will post -0.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AXGN has been the subject of several research reports. Raymond James initiated coverage on shares of AxoGen in a report on Monday, July 1st. They set an “outperform” rating and a $13.00 price target for the company. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Finally, JMP Securities upped their price target on shares of AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research note on Friday, August 9th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen presently has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.